Impax Laboratories Inc

Impax Laboratories — J.P. Morgan Global Healthcare Conference 2018

19 slides from Impax Laboratories's conference presentation, Jan 9, 2018

  1. Slide 1: J.P. Morgan Global Healthcare Conference January 9, 2018

    Slide 1: J.P. Morgan Global Healthcare Conference January 9, 2018

    J.P. Morgan Global Healthcare Conference January 9, 2018 +

  2. Slide 2: Safe Harbor statement

    Slide 2: Safe Harbor statement

    "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements are based o

  3. Slide 3: Important Information for Investors and Shareholders

    Slide 3: Important Information for Investors and Shareholders

    Important Information for Investors and Shareholders Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitatio

  4. Slide 4: A Strategic Combination for Long-Term Growth

    Slide 4: A Strategic Combination for Long-Term Growth

    A Strategic Combination for Long-Term Growth Creates 5th largest U.S. generics company Increases scale and diversification 4 ~200 marketed product families ~292 products filed and in development Data as of December 31, 2017. Combination Announced October 17, 2017; Closing Targeted First Half 2018 8

  5. Slide 5: Combination Fuels Long-Term Growth

    Slide 5: Combination Fuels Long-Term Growth

    ~$1.1 Pro Forma 2017E 2020E ~$0.60-$0.65 Combination Fuels Long-Term Growth Estimated Adjusted EBITDA*** ($billions) Growth Driven by a Diversified Portfolio of Generic Products Filed at FDA 5 ~22% CAGR  Annual double-digit revenue, adjusted EBITDA and adjusted EPS growth over next 3 years  Accret

  6. Slide 6: Poised for Success in Evolving Market Dynamics

    Slide 6: Poised for Success in Evolving Market Dynamics

    Poised for Success in Evolving Market Dynamics  Filed generic pipeline contains industry leading, high-value product opportunities* across multiple dosage forms  Fully diversified, cost efficient manufacturing and development capability focused on delivering high-value generic product opportunitie

  7. Slide 7: 2017 Achievements

    Slide 7: 2017 Achievements

    2017 Achievements 7  35 new products launched  36 ANDAs approved; 9 tentatively approved  48 ANDAs filed  Launched traimcinolone injection (first generic)  Launched thiotepa 15mg and 100mg injection (only 100mg product available)  Launched Aggrenox capsules and mometasone nasal spray  Filgras

  8. Slide 8: Combination Enhances Commercial Position

    Slide 8: Combination Enhances Commercial Position

    Combination Enhances Commercial Position  #1 or #2 position in ~50% of commercial portfolio*  Provides greater revenue diversification  Top 5 generic product net revenue contribution ~26%**  Opportunity to further capture long-term benefits of New Amneal development engine  NewCo has invested >

  9. Slide 9: Broad R&D Capabilities Across Dosage Forms

    Slide 9: Broad R&D Capabilities Across Dosage Forms

    Broad R&D Capabilities Across Dosage Forms Hyderabad, India: Injectables Cashel, Ireland: Respiratory Branchburg, NJ: Liquids, Inhalation, Nasal Sprays Brookhaven, NY: Oral Solids Piscataway, NJ: Oral Solids, Liquids, Topicals, Transdermals Hayward, CA: Oral Solids 9 Expected Annual Pro Forma Combin

  10. Slide 10: Diversified, High-Value New Amneal Pipeline

    Slide 10: Diversified, High-Value New Amneal Pipeline

    Diversified, High-Value New Amneal Pipeline ~292 total projects in the combined pipeline, of which ~50%+ are high value opportunities(1) Product data as of December 31, 2017. IMS Sales data as of November 30, 2017. (1) High value opportunities are eFTF, FTF, FTM and other high value opportunities wi

  11. Slide 11: Specialty Provides Stable Cash Flow

    Slide 11: Specialty Provides Stable Cash Flow

    Specialty Provides Stable Cash Flow Product Therapeutic Area Parkinson’s Disease Migraine Anthelmintic Anthelmintic 11

  12. Slide 12: Diverse and Extensive Manufacturing Capabilities

    Slide 12: Diverse and Extensive Manufacturing Capabilities

    Diverse and Extensive Manufacturing Capabilities Dahej, India: Active Pharmaceutical Ingredients (API) Vizag, India: Active Pharmaceutical Ingredients (API) Hyderabad, India: Oncology (vials and PFS) Ahmedabad, India: 3 Facilities: • 2 Oral Solids • 1 Injectables (Peptides, LA depot, Liposomes, PFS

  13. Slide 13: Significant Synergy Opportunity

    Slide 13: Significant Synergy Opportunity

    $80-$120 $125-$150 $200 Year 1 Year 2 Year 3 Significant Synergy Opportunity $200 million in expected annual synergies within 3 years* Builds on Impax’s existing cost improvement plan Enhanced internal capabilities and less reliance on 3rd party manufacturing, reducing costs and improving margin

  14. Slide 14: Integration Update

    Slide 14: Integration Update

    Integration Update  Enhanced leadership of combined company  Robert Stewart to serve as President and CEO  Paul Bisaro to serve as Executive Chairman  Chirag Patel and Chintu Patel will be Co-Chairmen of the Board  Pre-close integration work well underway  Regulatory review process progressing

  15. Slide 15: Significant Benefit from US Tax Reform

    Slide 15: Significant Benefit from US Tax Reform

    Significant Benefit from US Tax Reform The benefits of tax reform are not included in the $200 million of expected annual cost synergies. *Range of estimated rate is the result of sensitivity to projected jurisdictional mix as well as impact of US state and local taxes. 15 ~33% ~20-24%* 2017 2018 No

  16. Slide 16: Position New Amneal For Sustainable Long-Term Growth

    Slide 16: Position New Amneal For Sustainable Long-Term Growth

    Position New Amneal For Sustainable Long-Term Growth 16 Path Forward • Generics: Continuing internal R&D investment focused on all seven dosage forms • Specialty: Continuing focus on Movement Disorders pipeline and opportunistically in-license external opportunities INVEST IN ORGANIC GROWTH • Mainta

  17. Slide 17: Appendix

    Slide 17: Appendix

    Appendix

  18. Slide 18: New Amneal Leadership and Transaction Overview & Terms

    Slide 18: New Amneal Leadership and Transaction Overview & Terms

     New Amneal leadership  Paul Bisaro will be Executive Chairman  Chirag and Chintu Patel will be Co-Chairmen of the Board  Robert Stewart will be CEO  Bryan Reasons will be CFO  New Amneal Board of Directors (13 members)  Amneal will designate seven Board members including Chirag and Chintu Pa

  19. Slide 19: Combined PIV Disclosed Pending ANDA Pipeline

    Slide 19: Combined PIV Disclosed Pending ANDA Pipeline

    19 Combined PIV Disclosed Pending ANDA Pipeline $ millions. Source of sales data: IMS NPS November 2017; Pipeline data as of December 31, 2017. Product Brand LTM IMS Sales Product Brand LTYM IMS Sales Pemetrexed injection Alimta® $1,028 Guaifenesin + Dextromethorphan HBr Mucinex® DM $76 Lubiprostone

Source: SEC EDGAR · 425 filed Jan 9, 2018

More decks from Impax Laboratories Inc